Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma

By B. Leibovich, M. Blute, John C. Cheville, Christine M. Lohse, I. Frank, E. Kwon, A. Weaver, A. Parker, H. Zincke. Cancer, 2003

818 citations recorded by the source corpus.

Subfields: Epidemiology, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/d0191abcfdca844254ab180fe534dd98476214cb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Pulmonary and Respiratory Medicine

In Surgery

Citations in the corpus

Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome (2013, methodology): “Only patients with an initial intermediate or poor prognosis according to the Leibovich risk score [14] are eligible.”
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010, methodology): “The most recent modifications of the stage, size, grade and necrosis (SSIGN) score [18] (Table 3) and the University of California Los Angeles Integrated Staging System (UISS) (Table 4) [19] score are frequently used.”
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, methodology): “The most recent modifications of the stage, size, grade and necrosis (SSIGN) score [18] (Table 3) and the University of California Los Angeles Integrated Staging System (UISS) (Table 4) [19] score are frequently used.”
EAU guidelines on renal cell carcinoma: 2014 update. (2010, neutral): “For localised RCC, several risk scores and nomograms can be used, including the Stage, Size, Grade, and Necrosis Score (SSIGN) [44], a modified version of the SSIGN score (Leibovich score) [45] , and Karakiewicz's nomogram (LE 3) [47]; Section 3.7 provides further details.”
Treatment of renal cell carcinoma: Current status and future directions (2017, methodology): “One score, the SSIGN, was developed at the Mayo Clinic (also known as the Leibovich score) and classified patients with ccRCC into low-risk, intermediate-risk, or high-risk categories, according to stage, tumor size, nuclear grade, and the presence of tumor necrosis.(17,18) This score has been exter”
Renal cell carcinoma (2017, methodology): “The most recent modifications of the stage, size, grade and necrosis (SSIGN) score [18] (Table 3) and the University of California Los Angeles Integrated Staging System (UISS) (Table 4) [19] score are frequently used.”